ISAB has received an order from a new customer, a cutting-edge US pharmaceutical company developing novel antiviral therapies to treat a range of viral diseases from influenza to COVID-19. Initially the new customer will carry out in vitro dissolution testing using DissolvIt[®], ISAB's leading in vitro dissolution and absorption testing module.

DissolvIt[®] is one of a wide range of high-precision exposure modules that can connect to ISAB's central aerosol generation system PreciseInhale[®]. By using a unique "precision dosing" methodology, PreciseInhale[®] can generate the same aerosol across exposure modules that include in vivo, lungs ex vivo, and in vitro exposure and dissolution testing (DissolvIt[®]).

ISAB CEO Manoush Masarrat: "We are delighted to welcome this new customer and look forward to starting our collaboration with them. We are confident that the quality of our expertise and data will in turn help them to make the best possible decisions about their products' development moving forward."

READ MORE

Explore DissolvIt's capabilities here. (https://www.inhalation.se/inhalation-research-services/dissolvit-in-vitro-dissolution/)

Read ISAB's publications on DissolvIt[®] here. (https://www.inhalation.se/publications/)

Explore PreciseInhale's range of exposure modules here. (https://www.inhalation.se/products/)

Explore Inhalation Research Services here (https://www.inhalation.se/inhalation-research-services/)